02 . 10 .2023
Press release
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
29 . 07 .2023
Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement
27 . 07 .2023
Press release
Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology
04 . 07 .2023
Press release
Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4
28 . 06 .2023
Press release
WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology
26 . 06 .2023
Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round
19 . 04 .2023
Press release
Augmented reality: patient experience trumps misconceptions around injectables
30 . 03 .2023
Press release
AMWC 2023: Data from Sculptra® Cheek Wrinkle and Alluzience® Star Studies reinforce strength of Galderma’s broad aesthetic portfolio
18 . 03 .2023
Press release
AAD 2023: Late-Breaking Phase III results demonstrate nemolizumab’s significant impact on prurigo nodularis
13 . 03 .2023
Press release
Galderma delivers strong FY 2022 growth driven by innovation and commercial performance